Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550275 | 0.76 | ABCB1 (0.52) | ABCB1TSHR | |
| SCHEMBL367875 | 0.76 | FPR2 (0.52) | SMN1; SMN2TSHRFPR2 | |
| SCHEMBL2621666 | 0.76 | GAA (0.41) | POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL198057 | 0.74 | ABCB1 (0.50) | POLBABCB1TSHR | |
| SCHEMBL2621663 | 0.74 | POLB (0.50) | POLBLMNASMN1; SMN2TSHR | |
| SCHEMBL2949349 | 0.72 | ABCB1 (0.59) | ABCB1 | |
| SCHEMBL200546 | 0.72 | ABCB1 (0.49) | ABCB1TSHR | |
| SCHEMBL377244 | 0.72 | ABCB1 (0.59) | ABCB1 | |
| SCHEMBL377122 | 0.72 | ABCB1 (0.59) | ABCB1 | |
| SCHEMBL1965075 | 0.71 | FPR2 (0.47) | POLBLMNASMN1; SMN2TSHRFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| EP-2336123-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Neopharm Co., Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | NOX4 4284/4885POLB 4236/4885ABCB1 1260/4885 |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | NOX4 4284/4885POLB 4236/4885ABCB1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.